anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Men who have sex with men (MSM) is an inclusive term used to refer to phenotypic males who have insertive or receptive sex (penile-anal or penile-oral) with other phenotypic males, including people who are transgender or have other gender identities. MSM may report their sexual orientation as homosexual, bisexual, heterosexual, or something else, but this stated sexual orientation may not align with their sexual attraction or behaviors. Several health conditions disproportionately affect MSM compared with age-matched heterosexual men, including HIV infection, anal cancer, syphilis, and depression. Clinicians should use culturally sensitive questions to obtain a comprehensive sexual history and assess sexual risk. MSM should receive regular screening for HIV, hepatitis B and C, gonorrhea, chlamydia, and syphilis. Vaccinations for hepatitis A and B and human papillomavirus should be offered. MSM may benefit from preexposure prophylaxis to prevent HIV infection, postexposure prophylaxis to reduce the risk of HIV transmission, and counseling on safer sexual practices. Screening for anal cancer associated with human papillomavirus may be performed by digital anal rectal examination, although the optimal screening strategy has yet to be determined. Clinicians should also consider more frequent screenings for mental health issues in the MSM population because the rates of depression, suicide, substance use, and other psychosocial issues are higher than those of the general population.
To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. One will be 0.05 cc/kg of distilled water and the other 5 mg of haloperidol (in 2 cc syringes), 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
Nowadays, second-line treatment for SR-GVHD differs between centers and depends on the physician's experience. The agents commonly used as second and further lines of therapy include anti-thymocyte globulin, mycophenolate mofetil, calcineurin inhibitor, or extracorporeal photopheresis. However, the response varied. This study highlighted that corticosteroid (CS) is not a panacea for treating GVHD, and some patients with remission still experience further relapse. Additionally, the identification of multiple infections adds complexity.

Hope was supposed to come in 2019 after the Food and Drug Administration (FDA) approved RUX for the therapy of SR-GVHD in adult and pediatric patients \> 12 years. RUX add-on should be withheld as the risks outweigh the benefits, especially for patients who developed scleroderma and bronchiolitis obliterans. RUX can be added on as needed for the treatment of GVHD, especially in patients receiving DLI as relapse therapy with the conversion from mixed chimerism to complete chimerism. Despite some studies showing the efficacy of RUX across affected organs, some other data bring the opposite results. Thus we conducted this study to reinforce the efficacy of RUX as an add-on therapy for SR-GVHD.
Nausea is referred to as dysphagia and commonly known as choking or food backflow. The nausea is a symptom of naupathia and even vomiting caused when people feel upset stomach after food is swallowed, and is also referred to as gastric disorder. A recipe for treating the nausea takes Chinese medicinal herbs as raw materials, fine powder is extracted by a traditional medicament preparation method, and the recipe suits the remedy to the case according to the pathogenesis, does not have toxic or side effect and has a unique treatment effect. The recipe is applicable to patients suffering from dysphagia, choking, food backflow, nausea, stomach discomfort, naupathia and vomiting symptoms. The nausea recipe is repeatedly put into practice for years; based on clinical observation and healing of hundreds of cases, the total effective rate reaches 92%, and the cure rate reaches 91%; the nausea recipe has an obvious effect of regulating the middle-Jiao and functions of physical therapy and stomach qi transportation and transformation. The recipe is short in treatment course, quick in response, good in consolidation, convenient to administrate, safe and reliable, and is a unique holistic treatment secret recipe for treating the nausea.
Multilineage-differentiating stress enduring (Muse) cells are stage-specific embryonic antigen-3 (SSEA-3) positive cells that exist in mesenchymal stem cell (MSC) populations. Muse cells have the pluripotency to differentiate into all germ layers as embryonic stem cells. The purpose of the present study is to investigate the efficacy of Muse cell transplantation for repairing osteochondral defects. Muse cells were isolated from human bone marrow MSCs. As osteochondral defects, the patellar grooves of immunodeficient rats were injured. Next, cells were injected into the mice so that the animals were divided into the following 3 groups: a control group to which PBS was injected; a non-Muse group to which 5 x 10 4  SSEA-3 negative non-Muse cells were injected; and a Muse group to which 5 x 10 4  SSEA-3 positive Muse cells were injected. In the Muse group, repaired tissues with almost smooth and homogenous surface were observed 12 weeks after the treatment, while no repaired tissue was found in the control and non-Muse groups. Histological evaluation indicates that the Muse group showed better repair in the osteochondral defect sites 4 and 12 weeks after the treatment, compared to the other groups. Thus, Muse cells are likely a novel promising cell source for treating osteochondral defects.
There is growing concern about adverse developmental effects in infants and young children from prenatal exposure to environmental air pollutants, including polycyclic aromatic hydrocarbons (PAH), particulate matter (PM2.5), and environmental tobacco smoke (ETS). The proposed study combines expertise in molecular epidemiology and biomarkers, state-of- the-art pollutant monitoring techniques, and a strong theoretical framework to guide assessment of the impacts of these pollutants on fetal and child growth and development. The specific aims are: 1. To test the hypothesis that prenatal exposure to airborne polycyclic aromatic hydrocarbons (PAH) adversely affects fetal growth and early childhood growth and development, after controlling for non-PAH components of PM2.5, ETS, nutritional status (essential fatty acids and antioxidants) and other potential confounders; 2. To explore whether non-PAH components of PM2.5, and ETS have an independent effect on birth outcomes and childhood growth and development, after controlling for PAH, and to explore possible interactions between PAH, PM2.5 and ETS; and 3. To estimate the relative contribution of ambient PAH pollution vs. ETS and other indoor PAH sources to a) personal PAH exposure and PAH-DNA adducts and b) impairment of fetal growth and early child development. To achieve these aims, the international team of researchers will carry out a prospective cohort study of 400 nonsmoking pregnant women living in Krakow, Poland, and will follow their newborns for 12 months postnatally. Fetal growth will be assessed at birth by weight, length, head circumference, and size for gestational age. Childhood growth and developmental outcomes will be measured using the Fagan Test and the Bayley Scales. Strengths of the research include the combination of personal inhalation monitoring of PAH and PM2.5 with biomarkers (umbilical cord blood levels of PAH-DNA adducts, cotinine, essential fatty acids, antioxidants and lead) to estimate in utero exposure to the pollutants of interest and potential confounders. The Polish cohort provides a valuable model for study since emissions from coal burning and traffic are relatively high. However, the results will be broadly applicable since exposures to PAH, ETS and PM2.5 during pregnancy are common in virtually all industrialized regions of the world. It is anticipated that this research will provide relevant data to policymakers concerned with protecting the health of young children.
Significant elevation in blood pressure, including hypertensive crisis, has been reported on rare occasions in patients receiving 5-HT1 agonists with and without a history of hypertension. In clinical pharmacology studies, oral eletriptan (at doses of 60 mg or more) was shown to cause small, transient dose-related increases in blood pressure, predominantly diastolic, consistent with its mechanism of action and with other 5-HT1B/1D agonists. The effect was more pronounced in renally impaired and elderly subjects. A single patient with hepatic cirrhosis received eletriptan 80 mg and experienced a blood pressure of 220/96 mm Hg five hours after dosing. The treatment-related event persisted for seven hours.

Eletriptan is contraindicated in patients with uncontrolled hypertension (see CONTRAINDICATIONS).

An 18% increase in mean pulmonary artery pressure was seen following dosing with another 5-HT1 agonist in a study evaluating subjects undergoing cardiac catheterization.
During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Stroke Volume (SV) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if SV changes ≥10%, or no administration otherwise. Measurement of beat-to-beat stroke volume by intraarterial pulse contour analysis using the PiCCO system (Pulsion, Germany) will be used to assess stroke volume changes. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
An in vivo assay for assessing the metastatic potential of cancer cells has been developed. This is a functional assay that also allows for screening of compounds that are selective for metastatic cancer. Metastatic cancer is established in animals by intravenous injection of metastatic cancer cells before treatments are tested. This assay has been used to identify benzimidazoles for the treatment of metastatic prostate cancers. The benzimidazole(s) can be formulated for enteral or parenteral administration. In one embodiment, the compositions are formulated for parenteral administration. Compositions containing a benzimidazole exhibit greater cytotoxicity against cell lines prone to metastasis than against cells lines that are less prone to metastasis in vitro. The benzimidazoles described herein were effective at treating metastatic prostate cancer in bone. Administration of benzimidazoles in metastatic prostate cancer mouse models showed a significant increase in the survival times of the animals, even against paclitaxel resistant cancer cell lines.
BACKGROUND AND AIMS: Tsukushi (TSK) is a recently identified hepatokine, and we aimed to investigate the association between systemic TSK and the severity of nonalcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes mellitus (DM).
METHODS: Three hundred ninety-three DM and 289 without DM individuals were recruited for transient elastography assessment to determine liver steatosis and fibrosis. Serum TSK was measured by ELISA. The presence of NAFLD was defined as controlled attenuation parameter ≥ 248 dB/m.
RESULTS: NAFLD was present in 276 (70.2%) and 129 (44.6%) subjects with and without DM respectively, and they had higher serum TSK levels than those without NAFLD [DM group: 91.0 ng/mL (61.7-133.8) vs 82.5 (60.9-118.5), P < .01 respectively; without DM group: 97.1 ng/mL (69.3-148.6) vs 80.8 (53.4-111.6) respectively, P < .01]. Univariate analysis showed that serum TSK significantly correlated with the degree of steatosis and fibrosis both in subjects with and without DM. On multivariable regression analysis, only liver stiffness and estimated glomerular filtration rate were significant determinants of TSK level, and the relationship was independent of diabetes and serum adiponectin. Out of 405 subjects with NAFLD, 49 had either advanced fibrosis or cirrhosis. The area under receiver operating characteristic curve of serum TSK to indicate advanced fibrosis or cirrhosis was 0.70 (95% CI .62-.77), which was significantly better than that of fibrosis-4 index, 0.64 (95% CI .55-.72), P < .05.
CONCLUSION: Serum TSK levels were increased in subjects with NAFLD and reflected the severity of liver fibrosis.
Patients receive docetaxel IV over 10-30 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 or ramucirumab IV over 60 minutes and docetaxel IV over 10-30 minutes on day 1. Patients with non-squamous NSCLC receiving docetaxel and gemcitabine hydrochloride, also receive pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
FIELD: medicine, more precisely, neurology; applicable in correction of neurologic status in disseminated sclerosis. SUBSTANCE: method includes psychotherapeutic action to work out setting in patient for observation of norms of orthodoxy, fast, exclusion of alcohol, tobacco smoking, narcotics, pictures of living beings, and all types of plays. During the seances of psychotherapy, installed in room are vessels with water, isotonic solution of common salt, hemodez, vegetable oil, and all are used as remedial means. Solutions are introduced perorally, intramuscularly, intravenously, into vagina or urethra, or in form of clysma. Water is rubbed into haired part of head, or applications made from mixture of equal parts of flour, honey and hematoz. Baths are taken with addition of medicinal water, during this procedure, water is taken perorally, and then, contrast shower is taken. During treatment course, sauna is to be visited by 8-10 times and water is drunk in volume of 1000 ml. After sauna, air bath is taken for 1- 5 min, and physical training exercises in form of tonical stress and relaxation of all muscles are effected. EFFECT: reduced neurologic symptomatology.
Project Background: Acupuncture has been shown in other settings to alleviate symptoms of TBI that are reported to be precursors of post-concussion symptom, including affective (depression, anxiety) and somatic (headache, sleep difficulties) complaints. Evidence suggests that the increased intensity of these symptoms, particularly greater affective distress and injury-associated pain, increases vulnerability to neurodegenerative disease and PTSD. By treating post-TBI symptoms with acupuncture, these predisposing conditions will improve, and, as a result, the incidence of PCS in this patient population will be reduced.

Research plan: The overarching focus of this study is the use of acupuncture treatment, targeted to symptoms of mild TBI. The investigators propose a randomized, sham procedure and usual care-controlled clinical trial of acupuncture beginning at acute phase following mild traumatic brain injury (TBI). Participants meeting eligibility requirements will be randomized to 1 of 3 groups: verum acupuncture, sham acupuncture or waiting-list control. Acupuncture treatments will continue for one month, at which point all participants will be assessed for presence of mild TBI symptoms. Participants will be evaluated again after one-month acupuncture treatment and follow-up post-hospital discharge. The investigators hypothesize that true acupuncture will be more effective than sham acupuncture in reducing these outcomes at after treatment and follow-up stage. Patients were also scanned by 3T MRI scanner at baseline, one-month (after acupuncture treatment).
This invention is the sunscreen composition. It is the extract solution, which use polyol solvent to extract the Camellia seed dregs. The polyol can easily extract flavonoid glycosides, triterpene glycosides and other phenols from Camellia seed dregs. The extract solution in 200 nm~400 nm wavelength has strong absorption. Make good protection for skin and hair from UVA and UVB. It can be used as both the maintenance and the sunscreen products.
BACKGROUND: Long QT syndrome (LQTS) has been reported in older patients with advanced non-small cell lung cancer (NSCLC) following the use of osimertinib, the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). However, there have not been analytic epidemiology studies on this topic. We aimed to compare the risk of LQTS between osimertinib and first/second-generation EGFR-TKIs in older patients with advanced NSCLC.
RESEARCH DESIGN AND METHODS: This retrospective observational study used the 2006-2019 Surveillance, Epidemiology, and End Results (SEER)-Medicare data and included older patients with advanced NSCLC who were treated with either osimertinib or first/second-generation EGFR-TKIs during 2007-2017. Inverse probability of treatment weighting (IPTW) was used to balance the two groups with propensity scores estimated based on the patients' socioeconomic and clinical characteristics. Crude incidence rate (IR) and adjusted hazard ratio (HR) of the primary outcome, incident LQTS, were estimated.
RESULTS: A total of 545 and 1,135 patients were included in the osimertinib and first/second-generation EGFR-TKI groups, which increased to 1,614 and 1,659, respectively, after IPTW. The osimertinib group had a higher IR of LQTS (2.62 per 100 person-years, 95% CI 2.03-3.38) compared to the first/second-generation EGFR-TKI group (1.33 per 100 person-years, 95% CI 0.92-1.92). After adjusting for covariates, the osimertinib group had a higher risk of LQTS than the first/second-generation EGFR-TKI group, with an HR of 1.94 (95% CI 1.23-3.08). The increased LQTS risk in the osimertinib group was even higher in females, whites and patients aged ≥ 75.
CONCLUSIONS: Given the elevated risk of LQTS associated with osimertinib user, close monitoring for cardiac rhythm irregularities of high-risk patients following initiation of EGFR-TKI is recommended.
BACKGROUND: Spinal cord compression (SCC) is a severe complication in pediatric patients with relapsed, progressing, or refractory solid malignancies. This study aims to report the presentation, treatment, and role of proactive radiation therapy in these patients.
METHODS: This retrospective study reviewed 28 patients with relapsed, progressing, or refractory solid tumors who were referred for radiation therapy consultation due to potential (impending) or actual spinal cord compression (pSCC and aSCC, respectively) over a 12-year period. Collected data included disease characteristics, details of SCC events, management approaches, and patient outcomes.
RESULTS: Among the 28 patients, 34 SCC events were identified (18 pSCC, 16 aSCC), with neuroblastoma being the most frequent diagnosis (46.4%). No significant differences were noted between pSCC and aSCC groups in pre-event imaging follow-up, age distribution, or malignancy status at SCC presentation. However, aSCC patients exhibited significantly more symptoms at diagnosis. Both groups received SCC-targeted therapy, with no significant differences in functional outcomes, event-free survival (EFS), or overall survival (OS). Pain assessments post treatment showed comparable improvements in both groups.
CONCLUSIONS: Proactive radiotherapy for pSCC did not yield superior outcomes compared to reactive treatment for aSCC. Given the limited benefits observed, proactive RT should be considered on an individual basis, balancing potential QoL improvements against treatment burdens. Further research in larger cohorts is necessary to refine therapeutic strategies for SCC in pediatric oncology.
PURPOSE:To obtain the titled plaster easily applicable to human body and effective in continuously preventing especially armpit odor, by applying a tacky adhesive layer containing cyclodextrins to at least one surface of a substrate consisting of a stretchable nonwoven cloth or woven cloth. CONSTITUTION:The objective plaster for preventing armpit odor is composed of a substrate having a tacky adhesive layer on at least one surface of the substrate, wherein said substrate is composed of a stretchable nonwoven cloth or woven cloth and said tacky adhesive layer contains >=3wt.% of cyclodextrin and/or its derivative. Preferably, the liquid permeability of the plaster is restricted without lowering the stretchability by laminating the substrate with a stretchable film at the surface opposite to the tacky adhesive layer or laminating said substrate with said tacky adhesive layer interposing a stretchable film therebetween. Body odor, especially armpit odor can be eliminated continuously over a long period by applying the plaster to the armpit of human body. The plaster is resistant to peeling off and is applicable without causing disagreeable feeling or paint to the skin nor causing stuffing of the skin. Furthermore, the plaster can be easily peeled off from the skin as necessary.
The invention relates to a highly effective, pure, natural, nutritional, organic food product for consumption and plays a significant role in rejuvenation of health and well being. The invention provides for an edible product with a smooth texture, pleasant taste, aroma and natural flavours. The resulting food product is a consumable product which will prevent/treat ageing, rejuvenate youthfulness, virility, vigour and play a significant role in aiding health and wellness right from infants to elders. The invention relates to a nutritional, organic food product, which serves as a panacea for health, free of chemical pesticides, antibiotics, hormones, herbicides and chemical solvents. The resultant food product has superior stability over normal shelf life. The food product can be consumed in the form of chocolates, biscuits, pastries, cakes, sweets and other confectionary items, jams, jelly, juices, ice creams, in a powder form, pills, as a semi-solid or even in the form of solids.
Patients receive ruxolitinib phosphate PO every other day, QD, or BID on days 1-28. Each patient will be followed for a maximum of 96 weeks (24 cycles, 1 cycle is 4 weeks long). If the study drug continues to be effective, the patient may be eligible to continue on study drug past 24 cycles.
PURPOSE:To obtain complement-fixed particles which are easy to prepare, can be stored  for a long time, and show a peculiar agglutination reaction, by preparing complement- fixed particles within a specified particle size by fixing human or animal complements to particles prepared by immobilizing sugar onto organic macromolecular compounds. CONSTITUTION:In the diagnosis of specific diseases caused by an agglutination reaction to complements which are antibodies formed specifically against complements in human  or animal blood, monosaccharide or polysaccharide, such as D-galactosamine, is fixed to either hydrophobic copolymers, such as polystyrene, into which COOH, epoxy, OH or CONH2 radicals are introduced, or cross-linked hydrophilic macromolecules such as polymethacrylamide, either of which has particle sizes of 0.01-10mu. Next, fresh human or animal serum or the like is made to react therewith. Thereby the complements in the serum or the like are fixed thereto, and thus complement-fixed particles are obtained. When the particles thus prepared are made to react with specimen lymphocytes,  those having antibody components against the complements are fixed to these particles to thereby form rosettes. Thus the presence of antibodies against complements formed owing to malignant tumors, allergic diseases, etc. is detected. These complement-fixed particles show unchanged capability of forming rosettes even when they are stored for six months.